News

European EMA Confirms Severe Risks Associated with MS Medicine Zinbryta

A review of data concerning the multiple sclerosis (MS) medicine Zinbryta (daclizumab) confirmed its association with the risk of developing severe and potentially fatal immune reactions in the brain, liver and other organs, according to the European Medicines Agency’s (EMA)’s Pharmacovigilance Risk Assessment Committee (PRAC). Zinbryta was authorized…

Sativex Can Improve Driving Ability of MS Patients, Study Says

Sativex, a cannabis-based anti-spasticity medicine commercialized as oromucosal spray by GW Pharmaceuticals, improves the driving ability of patients with multiple sclerosis (MS), according to researchers. The findings were published in the journal Brain and Behavior, in a study titled “The influence of THC:CBD oromucosal spray…

National MS Society Welcomes Mud-Lovers to 2018 MuckFest MS

The National Multiple Sclerosis Society is inviting all mud-lovers to Saturday’s kickoff of MuckFest MS in Boston, Massachusetts, which raises money and awareness for multiple sclerosis (MS). The event includes a 5K “mud run” with “outrageous obstacles and a whole lot of mud” that definitely will make you sore “from…

Impact of Early Aggressive vs. Standard Therapy on Disability in RRMS To Be Tested in Trial

A Johns Hopkins University-initiated clinical trial is starting to enroll an estimated 900 relapsing-remitting multiple sclerosis (RRMS) patients to assess the benefits of switching therapies to prevent or reduce disability. The TREAT-MS study (NCT03500328) will evaluate whether RRMS patients with disease activity while on a traditional first-line disease-modifying therapy…